Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INVA 
Innoviva Inc (INVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: INVA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $36.2
1 Year Target Price $36.2
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.89% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.15B USD | Price to earnings Ratio 32.2 | 1Y Target Price 36.2 |
Price to earnings Ratio 32.2 | 1Y Target Price 36.2 | ||
Volume (30-day avg) 1 | Beta 0.41 | 52 Weeks Range 16.52 - 22.00 | Updated Date 10/24/2025 |
52 Weeks Range 16.52 - 22.00 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.44% | Operating Margin (TTM) 48.61% |
Management Effectiveness
Return on Assets (TTM) 8.83% | Return on Equity (TTM) 5.6% |
Valuation
Trailing PE 32.2 | Forward PE 7.27 | Enterprise Value 1065811002 | Price to Sales(TTM) 3.11 |
Enterprise Value 1065811002 | Price to Sales(TTM) 3.11 | ||
Enterprise Value to Revenue 2.88 | Enterprise Value to EBITDA 9.56 | Shares Outstanding 63021014 | Shares Floating 57648473 |
Shares Outstanding 63021014 | Shares Floating 57648473 | ||
Percent Insiders 0.98 | Percent Institutions 119.95 |
Upturn AI SWOT
Innoviva Inc
Company Overview
History and Background
Innoviva Inc. was founded in 1996 as Theravance, Inc., initially focusing on drug discovery. It evolved to focus on royalty management related to respiratory therapies developed in partnership with GlaxoSmithKline (GSK). In 2014, Theravance Biopharma, Inc. was spun off, and Theravance, Inc. was renamed Innoviva Inc.
Core Business Areas
- Royalty Management: Innoviva manages royalties from respiratory products developed with GSK, including TRELEGY ELLIPTA, RELVAR/BREO ELLIPTA, and ANORO ELLIPTA. It primarily focuses on maximizing the value of these assets.
Leadership and Structure
Innoviva Inc. is led by a Board of Directors and an executive management team. Specific details of the leadership team can be found on Innoviva's investor relations website.
Top Products and Market Share
Key Offerings
- TRELEGY ELLIPTA: TRELEGY ELLIPTA is a triple-therapy inhaler for COPD and asthma. Innoviva receives royalties on sales by GSK. Market share data is dependent on the overall market share of TRELEGY ELLIPTA for COPD and asthma treatments. Competitors include products from AstraZeneca, Boehringer Ingelheim, and Teva.
- RELVAR/BREO ELLIPTA: RELVAR/BREO ELLIPTA is a dual-therapy inhaler for asthma and COPD. Innoviva receives royalties on sales by GSK. Market share data is dependent on the overall market share of RELVAR/BREO ELLIPTA for asthma and COPD treatments. Competitors include products from AstraZeneca, Boehringer Ingelheim, and Teva.
- ANORO ELLIPTA: ANORO ELLIPTA is a dual-therapy inhaler for COPD. Innoviva receives royalties on sales by GSK. Market share data is dependent on the overall market share of ANORO ELLIPTA for COPD treatments. Competitors include products from AstraZeneca, Boehringer Ingelheim, and Teva.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the respiratory segment, is competitive and driven by innovation. It is characterized by stringent regulatory requirements, patent protection, and significant R&D investments.
Positioning
Innoviva's positioning relies heavily on its royalty rights to successful respiratory products marketed by GSK. Its competitive advantage stems from these established partnerships and revenue streams.
Total Addressable Market (TAM)
The global respiratory disease market is significant, estimated to be worth hundreds of billions of dollars. Innoviva benefits indirectly through royalties. Their positioning within this TAM is dependent on the success and market share of the products generating royalties.
Upturn SWOT Analysis
Strengths
- Established royalty streams from partnered products
- Strong partnership with GSK
- High profit margins due to royalty-based revenue
- Cash flow generation
Weaknesses
- Reliance on GSK for product sales and marketing
- Limited control over product development and commercialization
- Patent expiration risks affecting royalty streams
- Limited diversification
Opportunities
- Potential for new partnerships and collaborations
- Acquisition of new royalty streams or assets
- Expansion into adjacent therapeutic areas
- Strategic use of cash reserves
Threats
- Competition from other respiratory therapies
- Patent challenges and expirations
- Changes in GSK's strategy
- Regulatory changes affecting drug pricing and approvals
Competitors and Market Share
Key Competitors
- AZN
- LLY
- VRX
Competitive Landscape
Innoviva's competitive advantage lies in its established royalty streams. However, it lacks direct control over product sales and faces risks associated with GSK's performance and patent expirations. Competitors have their own marketed drugs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to sales of GSK-marketed products and royalty rates.
Future Projections: Future growth projections are based on analyst estimates. Refer to financial news outlets or Innoviva investor relations for accurate future projections.
Recent Initiatives: Recent initiatives are outlined in investor presentations and press releases. Refer to financial news outlets or Innoviva investor relations for accurate initiatives.
Summary
Innoviva's strength resides in its royalty-based business model and partnership with GSK. Revenue is tied to GSK's sales performance and patent protection on key drugs. Limited diversification and reliance on a single partner present risks. Effective capital allocation and strategic expansion could unlock further growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Innoviva Inc. Investor Relations
- Financial News Outlets
- Company Filings (SEC)
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share figures are approximations and may vary depending on the source and methodology. Financial data should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Innoviva Inc
Exchange NASDAQ | Headquaters Burlingame, CA, United States | ||
IPO Launch date 2004-10-05 | CEO & Director Mr. Pavel Raifeld C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 127 | Website https://www.inva.com |
Full time employees 127 | Website https://www.inva.com | ||
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.